TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Wanted: Volunteers for first human trial of COVID-19 vaccine in Indonesia

Bio Farma said that the tester team was looking for 1,620 volunteers in Indonesia as Sinovac would also conduct the trials in Brazil, Chile, Turkey and Bangladesh.

Moch. Fiqih Prawira Adjie and Riska Rahman (The Jakarta Post)
Jakarta
Wed, July 29, 2020

Share This Article

Change Size

Wanted: Volunteers for first human trial of COVID-19 vaccine in Indonesia In this picture taken on April 29, a researcher shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing. - Sinovac Biotech, which is conducting one of the four clinical trials that have been authorized in China, has claimed great progress in its research and promising results among monkeys. (AFP/Nicolas Asfouri )

S

tate-owned pharmaceutical holding company PT Bio Farma is looking for volunteers to assist in the clinical trial of a COVID-19 candidate vaccine developed in partnership with Chinese biopharmaceutical firm Sinovac Biotech, a ministry official has said.

Arya Sinulingga, an aide to State-Owned Enterprises Minister Erick Thohir, said the company was looking for Indonesians who fulfilled the requirements to help in testing the candidate vaccine for its first tryouts in the country.

Volunteers should be healthy adults between the age of 18 and 59 years old with no history of having contracted COVID-19 -- tested either through rapid or repeated polymerase chain reaction (PCR) tests, Arya said. Additionally, volunteers who register in the program should not participate in other clinical trials.

Should the registrants pass the administrative and other preliminary procedures, Bio Farma will administer them with the first dose of the experimental vaccine and later take their blood samples after 14 days.

After that, the company will give the volunteers a second dose and take their blood samples again after another 14 days.

“I will also register myself as a volunteer with Bio Farma,” Arya told reporters on Tuesday. “I have sent my ID card and I will enlist myself soon.”

“Hopefully, I can also invite other citizens to volunteer so we can contribute to the nation and the state,” he said, “Hopefully, this vaccine can be used in our nation and in others. I hope this will be successful.”

Read also: Indonesia teams up with global manufacturers in vaccine hunt

Padjajaran University in Bandung, West Java, and the Health Ministry will also assist in the clinical trial of the vaccine, Arya added.

The national COVID-19 task force previously said that the test would take place in Bandung.

Bio Farma secretary Bambang Heriyanto said recently that the human trials in Indonesia would be for the third phase as the candidate vaccine had passed the first and second human trial phases in China, kompas.com reported.

The first phase sought to test whether the vaccine would be safe for humans while the second phase examined its efficacy against COVID-19.

Bambang also said that the tester team was looking for 1,620 volunteers in Indonesia as Sinovac would also conduct the trials in Brazil, Chile, Turkey and Bangladesh.

Padjajaran University Medical School professor Kusnandi Rusmil previously said that he hoped the vaccine could pass the third phase as early as next January and could be followed by immediate distribution by the Health Ministry.

Bio Farma president director Honesti Basyir has outlined plans to distribute 40 million doses of the vaccine per year as soon as the government authorizes its widespread usage, with plans to expand distribution capacity to 250 million doses a year.

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.